• Product
• Concerns arise about securing COVID-19 treatment shortages
• by Kang, Hye-Kyung Aug 14, 2024 05:51am

• Company
• 'Xtandi and Erleada' compete in the prostate cancer market
• by Hwang, Byung-woo Aug 14, 2024 05:51am

• Opinion
• [Reporter's View] Delays in medication switching for eczema
• by Eo, Yun-Ho Aug 13, 2024 05:48am

• Company
• Nabota accounts for 24% of Daewoong’s ETC sales
• by Chon, Seung-Hyun Aug 13, 2024 05:47am

• Company
• 'High immunity vs. high dose’ flu vaccine for older adults
• by Hwang, Byung-woo Aug 13, 2024 05:47am

• Company
• Hanmi’s Rolvedon posts sales of KRW 20.6 billion in Q2
• by Son, Hyung-Min Aug 13, 2024 05:47am

• Company
• JAK inhibitors market size rose 54%↑over the year
• by Kim, Jin-Gu Aug 12, 2024 05:55am

• Company
• Columvi can be prescribed at general hospitals in KOR
• by Eo, Yun-Ho Aug 12, 2024 05:55am

• Company
• Anticancer drug 'Alecensa' expected to win nod
• by Eo, Yun-Ho Aug 12, 2024 05:55am

• Policy
• Reimb for Paxlovid still pending amid COVID-19 resurgence
• by Lee, Tak-Sun Aug 12, 2024 05:55am